276 related articles for article (PubMed ID: 27272791)
1. Targeted Therapies in HPV-positive and -negative HNSCC - Alteration of EGFR and VEGFR-2 Expression In Vitro.
Kramer B; Hock C; Birk R; Sauter A; Stuck BA; Hörmann K; Schultz JD; Aderhold C
Anticancer Res; 2016 Jun; 36(6):2799-807. PubMed ID: 27272791
[TBL] [Abstract][Full Text] [Related]
2. Small molecules alter VEGFR and PTEN expression in HPV-positive and -negative SCC: new hope for targeted-therapy.
Aderhold C; Faber A; Umbreit C; Chakraborty A; Bockmayer A; Birk R; Sommer JU; Hörmann K; Schultz JD
Anticancer Res; 2015 Mar; 35(3):1389-99. PubMed ID: 25750290
[TBL] [Abstract][Full Text] [Related]
3. Effect of selective small molecule inhibitors on MMP-9 and VEGFR-1 expression in p16-positive and -negative squamous cell carcinoma.
Kramer B; Schultz JD; Hock C; Sauter A; Stuck BA; Hörmann K; Birk R; Aderhold C
Oncol Lett; 2017 May; 13(5):3269-3276. PubMed ID: 28521433
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine Kinase Inhibition in HPV-related Squamous Cell Carcinoma Reveals Beneficial Expression of cKIT and Src.
Kramer B; Kneissle M; Birk R; Rotter N; Aderhold C
Anticancer Res; 2018 May; 38(5):2723-2731. PubMed ID: 29715092
[TBL] [Abstract][Full Text] [Related]
5. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
Aderhold C; Faber A; Umbreit C; Birk R; Weiss C; Sommer JU; Hörmann K; Schultz JD
Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847
[TBL] [Abstract][Full Text] [Related]
6. FGF Expression in HPV16-positive and -negative SCC After Treatment With Small-molecule Tyrosine Kinase Inhibitors and Everolimus.
Huber L; Birk R; Knuettel M; Rotter N; Aderhold C; Scherl C; Lammert A; Jungbauer F; Kramer B
Anticancer Res; 2020 Oct; 40(10):5621-5630. PubMed ID: 32988886
[TBL] [Abstract][Full Text] [Related]
7. HIF-1α and mTOR - Possible Novel Strategies of Targeted Therapies in p16-positive and -negative HNSCC.
Kramer B; Polit M; Birk R; Rotter N; Aderhold C
Cancer Genomics Proteomics; 2018; 15(3):175-184. PubMed ID: 29695399
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Aderhold C; Umbreit C; Faber A; Sauter A; Sommer JU; Birk R; Erben P; Hofheinz RD; Stern-Straeter J; Hörmann K; Schultz JD
Anticancer Res; 2013 May; 33(5):1951-61. PubMed ID: 23645743
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
[TBL] [Abstract][Full Text] [Related]
10. Impact of Small Molecules on β-Catenin and E-Cadherin Expression in HPV16-positive and -negative Squamous Cell Carcinomas.
Kramer B; Hock C; Schultz JD; Lammert A; Kuhlin B; Birk R; Hörmann K; Aderhold C
Anticancer Res; 2017 Jun; 37(6):2845-2852. PubMed ID: 28551620
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine Kinase Inhibitors and Everolimus Reduce IGF1R Expression in HPV16-positive and -negative Squamous Cell Carcinoma.
Kramer B; Schell A; Aderhold C; Huber L; Mueller CE; Rotter N; Birk R
Anticancer Res; 2020 Jul; 40(7):3847-3855. PubMed ID: 32620624
[TBL] [Abstract][Full Text] [Related]
12. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
14. Targeted Treatment of HPV16-positive and -negative SCC Cells With Small Molecule Tyrosine Kinase Inhibitors and Everolimus Affects MMP2 and MMP14 Expression.
Huber L; Birk R; Knuettel M; Rotter N; Aderhold C; Scherl C; Lammert A; Jungbauer F; Kramer B
Anticancer Res; 2022 Jul; 42(7):3403-3411. PubMed ID: 35790279
[TBL] [Abstract][Full Text] [Related]
15. Effect of Small-molecule Tyrosine Kinase Inhibitors on PDGF-AA/BB and PDGFRα/β Expression in SCC According to HPV16 Status.
Huber L; Birk R; Rotter N; Aderhold C; Lammert A; Jungbauer F; Kramer B
Anticancer Res; 2020 Feb; 40(2):825-835. PubMed ID: 32014925
[TBL] [Abstract][Full Text] [Related]
16. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
17. Small molecule-based chemotherapeutic approach in p16-positive and -negative HNSCC in vitro.
Aderhold C; Faber A; Grobschmidt GM; Chakraborty A; Bockmayer A; Umbreit C; Birk R; Stern-Straeter J; Hörmann K; Schultz JD
Anticancer Res; 2013 Dec; 33(12):5385-93. PubMed ID: 24324073
[TBL] [Abstract][Full Text] [Related]
18. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
[TBL] [Abstract][Full Text] [Related]
19. Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Umbreit C; Aderhold C; Faber A; Sommer JU; Sauter A; Hofheinz RD; Stern-Sträter J; Hoermann K; Schultz JD
Anticancer Res; 2013 Jun; 33(6):2457-65. PubMed ID: 23749896
[TBL] [Abstract][Full Text] [Related]
20. Expression Patterns of CD44 and AREG Under Treatment With Selective Tyrosine Kinase Inhibitors in HPV
Kansy B; Aderhold C; Huber L; Ludwig S; Birk R; Lammert A; Lang S; Rotter N; Kramer B
Cancer Genomics Proteomics; 2020; 17(5):579-585. PubMed ID: 32859636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
